0000000000544700

AUTHOR

G Zanchin

showing 2 related works from this author

Osmophobia in migraine classification: a multicentre study in juvenile patients.

2010

Aims: This study was planned to investigate the diagnostic utility of osmophobia as criterion for migraine without aura (MO) as proposed in the Appendix (A1.1) of the International Classification of Headache Disorders (ICHD-II, 2004). Methods: We analysed 1020 patients presenting at 10 Italian juvenile headache centres, 622 affected by migraine (M) and 328 by tension-type headache (TTH); 70 were affected by headache not elsewhere classified (NEC) in ICHD-II. By using a semi-structured questionnaire, the prevalence of osmophobia was 26.9%, significantly higher in M than TTH patients (34.6% vs 14.3%). Results: Osmophobia was correlated with: (i) family history of M and osmophobia; and (ii) o…

medicine.medical_specialtyPediatricsAdolescentAuraMigraine Disordersosmophobia juvenile primary headache migraine without aura tension-type headache International Classification of Headache Disorder 2nd ednInternational Classification of Headache Disorder 2nd edn; Juvenile primary headache; Migraine without aura; Osmophobia; Tension-type headache;International Classification of Headache Disorder 2nd ednlaw.inventionRandomized controlled triallawInternational Classification of DiseasesSurveys and QuestionnairesmedicinePrevalenceJuvenileHumansFamily historyChildosmophobiabusiness.industryOsmophobiaKeywordsGeneral Medicinemedicine.diseasetension-type headachejuvenile primary headacheMulticenter studyMigrainemigraine without auraChild PreschoolOdorantsSensation DisordersPhysical therapyInternational Classification of Headache DisordersNeurology (clinical)businessCephalalgia : an international journal of headache
researchProduct

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, …

2012

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were…

AdultTime FactorsOriginalMigraine DisordersPopulationAlmotriptanClinical NeurologyCarbazolesSubgroup analysisSeverity of Illness IndexAdult; Carbazoles; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Italy; Menstruation Disturbances; Middle Aged; Migraine Disorders; Proportional Hazards Models; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors; Treatment Outcome; TryptaminesDisability EvaluationDouble-Blind MethodAlmotriptanSeverity of illnessMedicineHumanseducationMigraine Menstrually related migraine Frovatriptan AlmotriptanMenstrually related migraineMenstruation DisturbancesMigraineMenstrually related migraineProportional Hazards Modelseducation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTryptaminesSerotonin Receptor Agonistsfrovatriptan; migraine; menstrually related migraine; almotriptanAnesthesiology and Pain MedicineTreatment OutcomeMigraineItalyAnesthesiaFemaleNeurology (clinical)businessFrovatriptanFrovatriptanmedicine.drug
researchProduct